Bharat Biotech to soon touch 1 billion COVAXIN doses per annum

Having already deployed multiple production lines at its Hyderabad and Bengaluru campuses, Bharat Biotech has recently added Chiron Behring to this line up of high containment BSL rated GMP facilities

0
157
Hyderabad: Bharat Biotech is looking at the quick ramp up of additional manufacturing capacities for COVAXIN at CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.
The company plans to produce 200 million doses of COVAXIN per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar is expected to commence from fourth quarter of the year 2021.
Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, now adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN. This effectively takes the volumes upto ~ 1 Billion doses per annum, with its own established campuses specialized for manufacturing inactivated viral vaccines under the highest levels of biosafety.